Transsphenoidal surgery for pituitary gigantism and galactorrhea in a 3.5 year old child.
The management of pituitary macroadenomas which lead to gigantism may require multiple therapeutical approaches, including medical treatment, surgery, and radiation therapy. Transsphenoidal surgery (TSS) during early childhood that achieves total removal of a growth hormone (GH) secreting tumor is rarely reported. The surgeon is confronted with special problems regarding the infantile anatomy. In this case, a 3.5 year old child, the youngest successfully treated by TSS so far, suffered from a GH- and prolactin (PRL) secreting macroadenoma of the pituitary gland. The girl initially presented with an increasing growth rate, later with breast development, and finally, at the age of 2.8 years, with galactorrhea and secretion of blood from the nipples. Increased levels of GH [122 micrograms/l], insulin-like growth factor (IGF-1) [830 micrograms/l], insulin-like growth factor binding protein 3 (IGFBP-3) [8.6 mg/l] and PRL [590 micrograms/l] were found. MRI scans revealed a macroadenoma of 2.7 cm diameter. An eight-week trial of relatively low dose dopamine agonists led to a reduction of PRL, while the GH- and IGF-1 levels remained unchanged; the tumor showed only little shrinkage. Since there was chiasma compression, we opted for early TSS. A complete tumor removal was achieved despite the difficulties of a narrow approach. After TSS, low levels of GH, IGF-1, and PRL documented a complete tumor removal, but persistent diabetes insipidus and anterior lobe deficits resulted from surgery. In summary, if primary medical therapy alone is unable to adequately reduce hormone hypersecretion and tumor size in early childhood, TSS is recommended. Thus, radiation therapy may be reserved for surgical failure.
Flitsch
J
J
Clinic of Neurosurgery, University Hospital Eppendorf, Germany. flitsch@uke.uni-hamburg.de
Lüdecke
D K
DK
Stahnke
N
N
Wiebel
J
J
Saeger
W
W
D001971:Bromocriptine / Q000627:therapeutic use; D002675:Child, Preschool; D018491:Dopamine Agonists / Q000627:therapeutic use; D005260:Female; D005687:Galactorrhea / Q000150:complications* / Q000188:drug therapy / Q000473:pathology / Q000601:surgery*; D005877:Gigantism / Q000150:complications* / Q000188:drug therapy / Q000473:pathology / Q000601:surgery*; D019382:Human Growth Hormone / Q000097:blood; D006801:Humans; D008279:Magnetic Resonance Imaging; D010911:Pituitary Neoplasms / Q000150:complications* / Q000188:drug therapy / Q000473:pathology / Q000601:surgery*; D011183:Postoperative Complications; D011388:Prolactin / Q000097:blood; D015175:Prolactinoma / Q000150:complications / Q000188:drug therapy / Q000473:pathology / Q000601:surgery; D013100:Sphenoid Bone / Q000601:surgery
D018491:Dopamine Agonists; D019382:Human Growth Hormone; D001971:Bromocriptine; D011388:Prolactin